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Abstract
The ability of embryonic stem cells to differentiate into endothelium and form functional blood vessels has been well
established and can potentially be harnessed for therapeutic angiogenesis. However, after almost two decades of
investigation in this field, limited knowledge exists for directing endothelial differentiation. A better understanding of the
cellular mechanisms regulating vasculogenesis is required for the development of embryonic stem cell-based models and
therapies. In this study, we elucidated the mechanistic role of insulin-like growth factors (IGF1 and 2) and IGF receptors
(IGFR1 and 2) in endothelial differentiation using an embryonic stem cell embryoid body model. Both IGF1 or IGF2
predisposed embryonic stem to differentiate towards a mesodermal lineage, the endothelial precursor germ layer, as well as
increased the generation of significantly more endothelial cells at later stages. Inhibition of IGFR1 signaling using
neutralizing antibody or a pharmacological inhibitor, picropodophyllin, significantly reduced IGF-induced mesoderm and
endothelial precursor cell formation. We confirmed that IGF-IGFR1 signaling stabilizes HIF1a and leads to up-regulation of
VEGF during vasculogenesis in embryoid bodies. Understanding the mechanisms that are critical for vasculogenesis in
various models will bring us one step closer to enabling cell based therapies for neovascularization.
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Introduction
Stem cell differentiation into endothelial cells is the first step of
vasculogenesis. [1–2] This process occurs spontaneously in vitro in
embryonic stem cell derived embryoid bodies (EB). [3] The
formation of vascular channels in EB closely mimics vasculogenesis
in vivo. [4] Many groups have attempted to preferentially drive
endothelial differentiation from embryonic stem cells but the
process remains inefficient or labor intensive. [5–6] Several critical
signaling factors have been identified, including , TGF-b, BMP4,
and VEGF, that drive the differentiation of pluripotent stem cells
first into mesoderm, endothelial progenitor cells and finally into
mature endothelium. [7–8] In a recent study, we demonstrated
that the cell surface glycome plays a critical role in this process. [9]
However, a better understanding of the signaling pathways that
control vasculogenesis is needed for efficient endothelial differen-
tiation.
Insulin-like growth factor (IGF) signaling mediates many critical
cell responses including mitogenesis, proliferation, growth, differ-
entiation, and angiogenesis. [10–12] IGFs circulate in the
bloodstream at nanomolar concentrations and are generally
bound to one of six IGF binding proteins (IGFBPs), which
regulate their availability to cell surface receptors. [13] Glycos-
aminoglycans also play a critical role in liberating the ligands from
their binding proteins and making them available to bind
receptors. [14] Insulin-like growth factors 1 and 2 (IGF-1 and
IGF-2) share about 50% of amino acid sequence with insulin and
have some affinity for the insulin receptor, but have distinct
physiological functions from insulin mediated by signaling through
the IGF-1 receptor. [15] Binding to this tyrosine kinase receptor
activates downstream PI3K and MAPK cascades that stimulate
growth and survival of particular cell types. IGF1R binds IGF1,
IGF2, and insulin with decreasing affinity. The IGF-2 receptor
(Man-6-P) is not a tyrosine kinase, and whether it elicits unique
downstream signaling pathways or acts as a ‘sink’ for IGF-2 is
relatively unknown. [16–18]
Insulin like growth factors are essential for embryonic
development. Both IGF1 and IGF2 are necessary to maintain
normal embryonic growth rates in mice and do not compensate
completely for one another. [19] Indeed, IGF2 has been shown to
play specific roles in adult development and disease. [20] IGF1
mutant mice display developmental bone defects and reach only
70% the size of wild-type mice. In contrast, overexpression of
IGF2 leads to fetal overgrowth and phenotypes similar to
Beckwith-Wiedemann Syndrome. [21] Complete absence of
IGF1R or of both IGF1 and IGF2 is embryonic lethal. While
several studies have shown a connection between IGFs and
neovascularization, their specific role in vasculogenesis is largely
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32191unknown. IGF1 has been shown to induce neovascularization and
endothelial proliferation in cornea and retina models. [22]
Similarly, IGF1R signaling from IGFs has been shown to mediate
neovascularization in human lung development and in zebrafish
cardiovascular development. [23–24] Previous studies have
implicated IGFs in stimulating endothelial progenitor cell
differentiation, migratory capacity, homing and incorporation
into existing vascular networks. [25–26] Mesoderm, the precursor
of blood vessels, muscle, bone and other specific lineages, have also
been shown to be dependent on insulin-like growth factors. [27]
Interestingly, studies have also established a role for the insulin-like
growth factor pathway in maintaining stem cell pluripotency. [28–
29] In this study, we investigated the role of insulin-like growth
factors 1 and 2 in embryonic stem cell vasculogenesis by focusing
on endothelial differentiation in embryoid bodies. Our results
establish that both IGF1 and IGF2 promote embryonic stem cell
differentiation into endothelial cells acting through the IGFR1
pathway.
Methods
Cell Culture and Materials
Mouse embryonic stem cell line 9TR#1 strain 129 was
obtained from ATCC. Embryoid bodies were induced by
seeding cells at a density of 3100 cells/cm
2 on neutrally charged
tissue culture plates (Corning). Mouse recombinant IGF-1 and
IGF-2 (R&D) were reconstituted in PBS and diluted to desired
concentrations immediately before use. Picropodophyllin (Enzo
Life Sciences) was reconstituted in DMSO and diluted to
desired concentration immediately before use. For all experi-
ments, IGF and PPP treatment doses were reconstituted to
desired dose in differentiation media and added to cells for
3 hours, after which media was replaced with fresh differenti-
ation media. Cells were treated daily with IGF-1 and IGF-2
beginning at day 1, and treated on alternate days with PPP, or
as indicated in the text. Neutralizing antibodies for IGFR-1 and
IGFR-2 (R&D) were added to EB (2 ng/mL) and incubated at
37uC for one hour before addition of 5 ng/mL IGF. Where
indicated, cells were serum starved and treated every other day
with 50 nM Rapamycin (Tocris) for 30 minutes prior to IGF
treatment.
Quantitative PCR
RNA was isolated at the indicated days using Aurum Total
RNA isolation kit and total RNA reverse transcribed using iScript
cDNA Synthesis kit. (Bio-Rad, Hercules, CA) The levels of
mRNA for specific genes were detected by using designed
oligonucleotide primers (IDT, Inc.) and monitoring SYBR Green
fluorescence. The normalized reporter (Rn) was calculated from
threshold values, Ct, for each gene as follows: Rn=2 X
2d C
T,
where d CT=(average CTtarget-average CTexperimental control) and
18S was used as endogenous control to normalize quantities of
cDNA.
Immunohistochemistry
EB were transferred to 0.1% gelatin coated coverslips on day 3
and differentiated as indicated above and with various treatments
as indicated. On day 7 (TIE-2) and day 10 (CD31), cells were fixed
with 4% PFA. TIE-2 (Santa Cruz), CD31 (Abcam), Alexa-
fluorH546 goat anti-rat (Invitrogen) AlexafluorH488 goat anti-
rabbit (Invitrogen) were incubated with cells for 1 hour at room
temperature (TIE-2) or overnight (CD31). Cells were counter-
stained with DAPI (Sigma). Images were obtained using a Nikon
Eclipse TI microscope and NIS-Elements 3.2 software.
Western Blotting
Indicated doses of PPP were added to cells and incubated for
4 hours, at which time cells were stimulated with 300 ng/mL
IGF1. For the analysis of HIF1a protein levels, cells were serum-
deprived overnight, and stimulated with indicated concentrations
of IGF1 for 2 hours, with or without 30 minute Rapamycin
treatment (50 nM). Primary antibodies Phosphorylated-IGFR1
Y1136, IGFR1, Phosphorylated AKT S473, AKT, P44/42
MAPK, actin (Cell Signaling), and ERK1/ERK2, HIF1a (Santa
Cruz) were incubated with membranes overnight at 4uC.
Quantification of protein levels was done using GeneTools H
software. Background was subtracted from protein raw values and
then normalized to levels of actin.
Flow Cytometry
Embryoid bodies were washed with PBS and disassociated using
0.25% Trypsin. Single cell suspensions were fixed in ice-cold
methanol and incubated with rat monoclonal antibody against
CD16/CD32 (Pharmigen, BD Biosciences) in order to block Fc
receptors. Cells were incubated overnight with VWF primary
antibody (DAKO) or isotype matched polyclonal IgG antibody
(Santa Cruz). Cells were washed and incubated with Alexa-
fluor488-conjugated secondary antibody and analyzed on a Accuri
C6 Flow Cytometer using CFlow Plus Software.
Statistical Analysis
All experiments were done in triplicate, unless otherwise noted,
and repeated to ensure consistent results. Statistical analyses were
performed by Prism H software (GraphPad Software, San Diego,
California) using one-way ANOVA and Newman-Keuls post-test
correction with acceptance level p,0.05. Data is presented as
mean +/2 SEM.
Results
IGF1 and IGF2 Treatment Increases Mesoderm
Development
Embryonic stem cells permitted to aggregate into cystic
embryoid bodies (EB) spontaneously differentiate into the three
germ layers which go on to differentiate into diverse lineages.
Vascular channels form in EB after approximately one week and
have been shown to recapitulate in vivo vascular development steps
and are thus a robust model for studying vasculogenesis. [4]
As a first step, we examined the expression of IGF1 and IGF2 as
well as their receptors in differentiating stem cells. Interestingly,
the expression of IGF1 was extremely high in undifferentiated cells
and then dropped and gradually rose with endothelial differenti-
ation, while IGF2 expression increased temporally with endothe-
lial differentiation. (Figure 1) The expression of IGFR1 and
IGFR2 paralleled that of IGF1 and IGF2 ligands. These results
are consistent with studies in the literature that have implicated the
signaling pathway in promoting stem cell pluripotency as well as
differentiation. Based on the results that IGF1 and IGF2 have
distinct expression patterns during endothelial differentiation, we
investigated their role in vasculogenesis.
To ascertain the effects of insulin-like growth factors on
vasculogenesis, we treated differentiating EB with increasing
concentrations of IGF-1 and IGF-2. After 3 hours, media
containing IGFs was removed and replaced with fresh media, as
continuous exposure to the growth factor caused receptor down-
regulation. (not shown) Treatment with IGF-1 or IGF-2 sign-
ficantly increased the differentiation of ES into mesoderm
compared to control, as measured mRNA levels of mesoderm-
specific marker, Brachyury, by quantitative PCR at day 3. The
IGFs Promote Endothelial Differentiation
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were not significantly affected by IGF treatment. (Figure 2A–2B)
Because insulin-like growth factors are known survival factors, we
wanted to ensure the effect was mesoderm specific. IGFs did not
significantly up-regulate endoderm and ectoderm specific markers,
APF and Pax6, leading us to conclude that the proliferating effects
of IGF-1 and IGF-2 were mesoderm specific. (Figure 2C–2D)
The increase in mesoderm generation peaked at approximately
5 ng/mL for IGF-1 but increased with concentrations up to
50 ng/mL for IGF-2. The biphasic concentration response seen
with IGF is consistent with similar observations in the case of other
angiogenic agents.
IGF1 and IGF2 treatment Increases Endothelial
Differentiation
To look at whether IGF treatment increases differentiation of
ES into mature endothelial cells, we considered the mRNA levels
Figure 1. Expression of Insulin Like Growth Factors, Receptors, and Binding Proteins with Embryonic Stem Cell Differentiation. A)
mRNA levels of IGFR-1, IGFR-2, IGF1, and IGF2 increase with time in differentiating embryoid bodies measured from days 1–7, although IGF1 appears
to remain steady, pointing to its role in both pluripotency and differentiation. * denotes P,0.05 to day 1 control, Rn denotes normalized reporter.
doi:10.1371/journal.pone.0032191.g001
Figure 2. IGF1 and IGF2 promote mesoderm and endothelial differentiation. A–B) Day 3 EB treated with IGF1 and IGF2 display increased
mRNA levels of Brachyury and no significant change in Oct4, Nanog, and Sox2. C–D) Levels of AFP and PAX6 are not affected. # denotes P,0.05, Rn
denotes normalized reporter. Day 7 EB treated with IGF1 (E,F) and IGF2 (G,H) possess increased levels of endothelial specific markers.
doi:10.1371/journal.pone.0032191.g002
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day 7 EB. EB treated with IGF1 or IGF2 expressed significantly
higher levels of endothelial markers compared to untreated
control. (Figures 2E–2J) The optimal concentration of IGF1 or
IGF2 to enhance vasculogenesis was approximately 2–5 ng/mL,
which resulted in increased expression of endothelial markers as
high as 7-fold compared to control. For future experiments, we
used 5 ng/mL as the optimal dose of IGFs to induce endothelial
differentiation. A marker of functional endothelium, Von Will-
ebrand Factor (VWF) was also specifically upregulated along with
markers associated with endothelial progenitor cells, suggesting
that IGFs promote development of a mature, functional
endothelial cells. (Figure S1A) Because IGF promoted differen-
tiation appears to be specific for the mesoderm lineage, we also
looked at the mRNA expression of a panel of mesoderm markers
at 7 days following daily IGF1 and IGF2 treatment in
differentiating EB including those for cardiomyocyte, skeletal
myocyte and hematopoietic lineages. Although IGF1 treatment
did result in a significant increase in alpha-myosin heavy chain
aMHC (muscle specific) and b-globin (erythroid specific) mRNA
expression, there was no significant change or a significant
decrease in markers of other mesoderm lineages. (Figure S1B–
S1F)
Inhibition of IGFR-1 blocks effects of IGF1 and IGF2
treatment and suppresses endothelial differentiation
To look closer at IGF signaling, we investigated the effects of
blocking Insulin-like Growth Factor Receptor 1 (IGFR-1), the
major receptor through which IGF-1 and IGF-2 signal. A
neutralizing antibody for IGFR-1 significantly inhibited the effects
of IGF1 and IGF2 on differentiating EB. Levels of endothelial
specific markers are substantially reduced when EB are treated
with IGFR-1 antibody, as seen in EB immuno-stained for
progenitor and mature endothelial marker TIE2. Differentiated
7 day EB treated with 5 ng/mL IGF1 and IGFR-1 neutralizing
antibody exhibited minimal TIE2 staining compared to control
cultures wherein regions of TIE2 staining appear within vascular
structure outgrowths. (Figure 3A). This was confirmed by
quantitative PCR, where IGFR-1 neutralizing antibody signifi-
cantly decreased the endothelial enhancing effects of IGF1 and
IGF2, as measured by levels of VEGFR2 and TIE2. (Figure 3B)
In contrast, IGFR-2 neutralizing antibody failed to exert any
significant reduction in IGF-induced vascular differentiation.
(Figure 3C) These results indicate that the effects of IGFs on
mesoderm development and vasculogenesis are mediated specif-
ically through IGFR-1 signaling.
Picropodophyllin (PPP), is a selective inhibitor of IGFR-1 which
binds to its Tyrosine 1136 residue and blocks its capacity for
autophosphorylation and downstream signaling. We demonstrated
that PPP inhibits phosphorylation of IGFR-1 at the expected
phosphorylation site as well as inhibits phosphorylation of
downstream signaling targets, AKT and ERK. (Figure 4)
Treatment of EB with PPP inhibited ES mesoderm differentiation
as measured at day 3. Levels of pluripotency markers Nanog and
Sox2 were significantly increased, whereas mesoderm marker
Brachyury was decreased. (Figure 5A) Futhermore, at one week,
PPP significantly inhibited endothelial differentiation, as indicated
by levels of VEGFR2, TEK, and VE-CADH. (Figure 5B)
Figure 3. Inhibition of IGFR1, but not IGFR2, inhibits vasculogenesis in differentiating embryoid bodies. A) Tie-2 expression in is
decreased in EB treated with IGFR1 neutralizing antibody (nAb IGFR1). Tie-2 expression (FITC), DAPI nuclear counterstain. B) IGFR1 neutralizing
antibody treatment (Antibody/Ab) significantly reduces levels of endothelial markers. C) IGFR2 neutralizing antibody treatment had no significant
effects on levels of VEGFR2 or Tie-2. * denotes P,0.05 to control, Rn denotes normalized reporter.
doi:10.1371/journal.pone.0032191.g003
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with 12 nM PPP severely decreased the development of
vasculature in differentiated embryoid bodies compared to
controls at day 10. (Figure 5C)
IGFs promote EB differentiation at various stages in the
vasculogenesis pathway
Based on the above results, we further investigated whether
IGFs increase endothelial development by simply increasing
mesoderm differentiation, or play at role at other stages of
vascular development. Indeed, EB treated with IGFs at early
stages of differentiation before mesoderm development, treated on
days 1 and 2 only, displayed increased numbers of endothelial cells
after one week as measured quantitatively by levels of VEGFR2
mRNA. However, EB treated post-mesoderm development with
IGF-1 and IGF-2 also contained increased levels of endothelial
cells compared to controls but a higher dose of IGF was required
to see this effect. (Figure 6A–6B) These results indicate that one
of the major means by which IGFs enhance vasculogenesis is by
stimulating mesoderm development but that IGFs also enhance
endothelial development at later stages in differentiation. To
further confirm the IGF-promoted increase in endothelial specific
differentiation, we used flow cytometry to quantify the percentage
of differentiation endothelial cells when cells were treated with
IGFs post-mesoderm development. As measured by positive
staining for VWF compared to isotype control, the mean
percentage increase of endothelial cells compared to control was
7.56 with IGF1 treatment and 3.67 with IGF2 treatment (n=4).
(Figure 6C) Treatment with PPP before day 3 also severely
decreased the number of endothelial cells at one week, as did
treatment after mesoderm development. (Figure 6D–6H) Taken
together, the data indicates that IGFs enhance both differentiation
of mesoderm, as well as other stages of endothelial lineage
differentiation.
IGFs increase HIF1a stabilization and expression of
Vascular Endothelial Growth Factor
To further explore the mechanisms underlying IGF-induced
vasculogenesis, we studied the effect of IGF treatment on the
expression of HIF1a in EB. Previous studies have indicated that
IGF can stabilize HIF1a, an important regulator of VEGF
expression in neovascularization. [30] As seen in Figure 7A,w e
demonstrated that HIF1a protein levels were significantly
increased by approximately two-fold following stimulation with
IGF1. Stabilization and translocation of HIF1a to the nucleus is
one of the major stimuli for VEGF transcription. [31] Indeed, we
confirmed that VEGF expression was significantly increased at day
3 and day 7 following treatment with IGF1 or IGF2, and
treatment of EB with PPP decreased VEGF levels (Figure 6E–
6G). Furthermore, treatment of differentiating cells with rapamy-
cin significantly decreased IGF-induced increase in HIF1a protein
levels and inhibited VEGF transcription as well as VEGFR2 levels.
Figure 4. Picropodophyllin treatment decreases IGFR1 signaling and downstream AKT and ERK signaling. A) IGFR1 Y1136
Phosphorylation was inhibited with picropodophyllin (PPP). A random pharmacologic control drug, PHA, had no effect on IGFR1 phosphorylation. B)
PPP treatment significantly decreases downstream AKT S473 phosphorylation and ERK p44/p42 phosphorylation (C). * denotes P,0.05 compared to
control. (n=3).
doi:10.1371/journal.pone.0032191.g004
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wherein IGF treatment activates downstream PI3 Kinase and
MAP Kinase pathways leading to stabilization of intracellular
HIF1a, which in turn up-regulates transcription of VEGF, the
critical endothelial cell differentiation factor. (Figure 7C)
Discussion
We have determined, for the first time, the direct effects of IGF1
and IGF2 on vasculogenesis in an embryoid body system (EB). Our
resultsdemonstratethattreatmentwith IGF1 and IGF2 increasethe
generation of endothelial cells in a spontaneously differentiating EB
model. Daily pulse treatment of EB with IGFs caused a significant
increase in mesoderm generation which translated to increased
differentiation into endothelium compared to control. Interestingly,
we did not see a significant increase in mRNA levels for Pax6 or
AFP, markers of ectoderm and endoderm, suggesting that the effect
is specific for the mesoderm lineage and importantly, and is not
simply due to the proliferation of all cell types. To see if this was the
reason for the increased number of generated endothelial cells, we
treated EB with IGFs only after mesoderm formation. Treatment
with IGFs after day 3 also caused a significant increase in
endothelial differentiation at one week. These results suggest that
insulin-like growth factorsplay a role in promoting vasculogenesis at
both of these critical stages. Although the percentage of differen-
tiated endothelial cells increased by only 7.6% and 3.7% with IGF1
and IGF2 post-mesoderm development, this represents a substantial
increase in differentiation considering the most potent vasculogenic
factor VEGF was shown to increase differentiation in EB by
approximately10%andfurtherconfirmsthatIGFtreatmentplaysa
specific role in the endothelial pathway. [4] Furthermore, although
treatment with IGF1 did result in significant increase of some other
mesoderm lineage markers, the optimal IGF1 and IGF2 treatment
dose for promoting vasculogenesis did not result in increased
differentiation of all mesoderm lineages. This corroborates previous
studies which have shown that IGFs promote both mesoderm
formation [27], and endothelial progenitor cell mobilization and
differentiation in functional endothelium. [32] Insulin-like growth
factors have previously been shown to promote differentiation of
several cell types, including neurons, myocytes and osteoblasts. [33–
35] IGF in combination with other growth factors like VEGF and
FGF, has been shown to induce optimal endothelial differentiation
from stem cells, but to our knowledge ours is the first mechanistic
study to look directly at IGF-1 and IGF-2 treatment alone using an
embryonic stem cell vasculogenesis model. [36–37]
Bendall et al. discovered that IGF2 was sufficient in maintaining
human ES self-renewal and pluripotency and postulated that a
subset of ES generate a source of the ligand to maintain
Figure 5. Picropodophyllin treatment inhibits mesoderm and endothelial formation in differentiating embryoid bodies. Day 3 EB
treated with PPP have unchanged or increased levels of pluripotency markers significantly decreased levels of Brachyury. B) PPP treatment decreases
expression of vascular markers at day 7. C) Differentiated EB cultures treated with PPP and stained for CD31 (TRITC) had strikingly less vessels
compared to control on day 10. *denotes P,0.05, Rn denotes normalized reporter.
doi:10.1371/journal.pone.0032191.g005
IGFs Promote Endothelial Differentiation
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32191undifferentiated cultures. [28] Chen and Khillan demonstrated
that retinol signaling through IGFR1 led to maintenance of self-
renewal and pluripotency in mouse ES. [38] Both studies proposed
that the downstream PI3K/AKT pathway was critical for these
effects. Indeed, stem cells balance a large number of signaling
pathways and subtle shifts in signaling can effectively cause a cell
to remain pluripotent or progress along a particular differentiation
pathway. Proliferation and differentiation of myoblasts upon IGF
treatment were shown to utilize separate downstream pathways.
The MAPK pathway was critical for optimal proliferation after
IGF-1 stimulation, while PI3K signaling was required for
differentiation. [33]
The treatment specifics and context play a large role in
determining the downstream effects of IGF treatment on ES. For
example, we saw a large difference in mRNA levels when cells
were treated continuously with IGF or picropodophyllin com-
pared to ‘pulse’ treatment where media was replaced with fresh
control media after specified times; continuous treatments caused
a significant down-regulation of IGFR1 and IGFR2. Differential
expression of IGF binding proteins could also influence the effects
of IGF at various cellular stages. Additionally, in our studies,
treatment with IGFs or PPP began after 24 hours of culturing cells
in low-adherent conditions, when they have likely gained some
differentiation capacity. These results indicate that the availability
of insulin like growth factors is tightly regulated to control their
cellular affects.
We confirmed that one of the mechanisms by which IGF
promotes vasculogenesis is by HIF1a-mediated up-regulation of
VEGF. Indeed, we demonstrate significant up-regulation of VEGF
mRNA after treatment with IGF1 or IGF2. The doses that
produced optimal VEGF upregulation corresponded with those
that stimulated the most endothelial differentiation. Picropodo-
phyllin, the specific inhibitor of IGFR1, significantly decreased
VEGF mRNA levels. VEGF signaling is the decisive factor for
mesoderm cells to commit to the endothelial lineage differentiation
pathway; it is also a major stimulus for differentiation of
endothelial progenitor cells into mature endothelium. Picropodo-
phyllin (PPP) is a cyclolignan that inhibits IGFR1 activation by
Figure 6. IGFs induce endothelial differentiation at early and late stages of vasculogenesis and increase expression of VEGF. A–B)
VEGFR2 and Tie-2 levels at day 7 are significantly increased in EB treated on days 1 and 2 only or on days 4–7 only. C) Treatment with IGF1 or IGF2
post-mesoderm development results in an increase in the percentage of VWF-positive cells compared to control differentiation EB. D–E) PPP
treatment on days 1 and 2 only or on days 4–7 only reduced levels of endothelial markers at day 7. Levels of VEGF increased with IGF1 and IGF2
treatment, and decreased with PPP treatment (F–H), at day 3. * denotes P,0.05 compared to control ** P,0.01, Rn denotes normalized reporter.
doi:10.1371/journal.pone.0032191.g006
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tyrosines on the intracellular receptor domain, while having no
effect on the phosphorylation of closely related insulin receptor or
non-related tyrosine kinase receptors including FGFR, PDGFR,
and EGFR, nor did it down-regulate insulin, VEGFR, EGFR, or
PDGFR. [39–40] PPP was shown to inhibit IGFR1 signaling in a
multiple melanoma mouse model leading to reduced levels of
VEGF and a significant reduction in angiogenesis and increased
survival. [41] IGF induced up-regulation of VEGF secretion was
also blocked by PPP in choroid tumors and Kaposi sarcoma. [42–
43] IGF1 has been shown to upregulate VEGF in many cell types,
including colon cancer, pancreatic cancer, fibroblasts, and
osteoblasts. [44–45]
HIF1a is a major transcriptional activator of VEGF and VEGF
receptors and a major stimulus for embryonic vasculogenesis and
neovascularization in embryoid bodies. [46] In normoxic
conditions, the protein is degraded by the ubiquitin pathway,
but is stabilized in hypoxic conditions and goes on to transcribe
genes critical for vasculogenesis, metabolism and cell survival.
Inhibition of HIF1a in ES dramatically inhibits levels of VEGF
and results in reduced vascular development. [47–48] HIF1a
synthesis is activated by various oncogenes, cytokines, and growth
factors. [31] IGF-1 has been established as a posttranscriptional
stimulator of HIF1a accumulation, nuclear translocation, and
activity. [30] IGF1 increases HIF1a protein levels and VEGF
transcription in Kaposi Sarcoma which is inhibited by treatment
with PPP. [49] IGFR1 signaling mediated through downstream
AKT and MAPK pathways leads to increased levels of HIF1a and
VEGF in pancreatic, colon, and other cancers and therefore was
investigated as an anti-angiogenic target. [45] We have shown that
IGF1 stimulation of embyroid bodies causes and increase in levels
of HIF1a protein in embryoid bodies. Treatment with HIF1a
inhibitor rapamycin inhibits intracellular protein levels of HIF1a
and blocks IGF-induced increase in VEGF transcription and
endothelial progenitor differentiation. This suggests that the
HIF1a/VEGF axis is one of the key mechanisms through which
IGF1 and IGF2 increase endothelial differentiation. Further,
HIF1a has been shown to increase transcription levels of IGF2,
resulting in an autocrine IGFR1 activation/VEGF expression
loop. [50]
Our study establishes a convincing role for both IGF1 and IGF2
in stimulating a substantial increase in vasculogenesis in embryonic
stem cells. Understanding the mechanisms which regulate vascular
development in various models, like the EB, can lead to a better
understanding of neovascularization in vivo. Treatments at various
stages of differentiation revealed that IGFR1 signaling promotes
Figure 7. IGF1 increases HIF1a protein levels in differentiating embryoid bodies and inhibition of HIF1a with rapamycin decreases
VEGF and VEGFR2 expression in embryoid bodies treated with IGF1. A) HIF1alevels increase significantly following treatment with IGF1.
Rapamycin reduces protein levels when added to cell cultures prior to IGF1 stimulation. * denotes P,0.05 compared to conrol, ** denotes P,0.05
compared to +IGF B) Day 3 EB treated with IGF1 express significantly higher levels of VEGF and VEGFR2 compared with control (# denotes P,0.05
compared with control), which are significantly inhibited by treatment with HIF1a inhibitor rapamycin. (* denotes P,0.05 compared to IGF1
treatment). C) Proposed mechanism of IGF1 and IGF2 stimulated endothelial differentiation.
doi:10.1371/journal.pone.0032191.g007
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progenitor cells into mature endothelial cells, indicating that IGFs
can emerge as a powerful tool for enabling vascular regeneration
therapies.
Supporting Information
Figure S1 IGF treatment has different effects on various
mesoderm lineage differentiation. Daily treatment with
IGF1 and IGF2 had mixed results on mRNA levels of transcripts
specific for various mesoderm lineages: A) Functional endothelial
marker, VWF B) Cardiomyocyte transcription factor Nkx2.5 C,D)
Muscle specific a-MHC and myogenin E,F) hematopoietic lineage
transcripts b-globin and GATA1. (* denotes P,0.05 compared to
control)
(TIF)
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